Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of isotretinoin in severe recalcitrant acne
jRCT2031240401Phase 3Completed
- Sponsor
- Sun Pharma
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of isotretinoin in acne vulgaris (2 arms), sponsored by Sun Pharma. Primary endpoint: Proportion of patients with at least 90% reduction in inflammatory nodular/cystic lesions. Started Nov 2024; status: completed.
02
Drugs
isotretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on jRCT2031240401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240401.